SSY Group (HKG:2005) obtained registration approval from China's National Medical Products Administration for riluzole to become a bulk drug for preparations on the market, a Thursday Hong Kong bourse filing said.

The drug is mainly used to prolong the life of patients with amyotrophic lateral sclerosis (ALS) or the time it develops to require mechanical ventilation support.